Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal GSK2245035 in mild allergic asthma
2015-005645-31Phase 2Completed
- Sponsor
- GSK
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic asthma comparing GSK2245035 intranasal with Placebo intranasal (2 arms). Primary endpoint: Late asthmatic response (LAR). Started May 2016; status: completed.
02
Drugs
GSK2245035
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2015-005645-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005645-31.